Shares of Xenon Pharmaceuticals Inc. (XENE) jumped in Monday's premarket session. The reason? Some very good news about a drug that helps people have fewer seizures.

The company announced positive results from its big Phase 3 clinical trial, called X-TOLE2, for its drug candidate azetukalner. The drug is being tested for treating focal onset seizures, a common type of epilepsy.

The Data Looks Really Good

The main goal of the study was to see how much the drug could reduce monthly seizure frequency. It didn't just meet that goal—it crushed it. For patients on the 25 mg dose, the placebo-adjusted median percentage change was a reduction of 42.7%. That's a major drop.

To put that in perspective, this new data is even better than what the company saw in its earlier Phase 2b study. That previous study showed a 34.6% reduction for the same dose. So, the latest results represent a meaningful improvement.

There was another win, too. A key secondary measure looked at how many patients saw their seizure frequency cut in half. In the 25 mg group, 54.8% of participants hit that mark, compared to just 20.8% in the placebo group. That's a strong response rate.

With this data in hand, Xenon is now planning its next big move: asking the FDA for approval. The company expects to submit a New Drug Application in the third quarter of 2026. If approved, azetukalner would be in a class of its own—the only KV7 potassium channel opener available for treating epilepsy. For patients whose seizures aren't well-controlled by current medicines, that could be a game-changer.

Analysts Are Impressed

Wall Street was watching closely, and the reaction has been positive. Analysts at William Blair pointed out that investors were debating whether the drug needed to show a 25% or 30% reduction to be considered a success. The 42.7% figure, as they noted, "clearly blast through both" of those bars.

Analyst Myles Minter sees significant commercial potential, estimating that azetukalner could achieve up to $2.6 billion in worldwide peak sales. He also provided some context, noting that peers in the anti-seizure medication space have recently seen even larger sales estimates. For example, Praxis Precision Medicines Inc. (PRAX) and Rapport Therapeutics Inc. (RAPP) have had peak sales estimates for their lead drugs exceed $4 billion and $2 billion, respectively.

What's Happening with the Stock?

The stock is showing some strong technical momentum. It's currently trading 13.9% above its 20-day simple moving average and 15.3% above its 100-day simple moving average. Over the past year, shares are up 22.40% and are sitting closer to their 52-week highs than their lows.

Some other technical indicators are giving mixed signals, though. The Relative Strength Index (RSI) is at 46.09, which is considered neutral—not overbought or oversold. Meanwhile, the Moving Average Convergence Divergence (MACD) is below its signal line, which some traders read as a bearish signal. So, the momentum picture isn't perfectly clear.

For traders watching key levels, the stock has notable resistance around $50.00 and support around $39.00.

The analyst community remains bullish. The consensus rating is a Buy, with an average price target of $56.78. Recent analyst actions include:

• Needham: Buy rating, raised price target to $58.00 (Feb. 27)
• Wells Fargo: Overweight rating, raised price target to $49.00 (Feb. 27)
• Wolfe Research: Initiated coverage with an Outperform rating and a $60.00 price target (Feb. 24)

For investors who prefer getting exposure through exchange-traded funds (ETFs), Xenon is a holding in the iShares Neuroscience and Healthcare ETF (IBRN), with a weighting of 3.66%.

Putting it all together, Xenon Pharmaceuticals shares were up 16.17% at $48.72 in premarket trading on Monday. It's a big move for a Monday morning, all thanks to some promising data for patients who need better options.